Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients: 24-week immunological outcome

MeSH terms

• Antiretroviral Therapy, Highly Active
• CD4 Lymphocyte Count
• Drug Administration Schedule
• Drug Resistance, Multiple, Viral*
• HIV Infections / drug therapy*
• HIV Infections / immunology
• HIV Protease Inhibitors / administration & dosage*
• HIV Protease Inhibitors / therapeutic use
• HIV-1*
• Humans
• Linear Models
• Treatment Outcome